About
Nintx (Next Innovative Therapeutics) was originated in Brazil at the beginning of 2021 to translate complex biological interactions (plants, microorganisms, and humans) into novel therapies.
Nintx views plant-based natural products as having a huge potential to modulate human biological targets directly (inherent physiological function) and indirectly via modulation of the gut microbiome (interspecies molecular crosstalk) to generate multi-target therapies.
Nintx leverages the functional legal and regulatory frameworks to access the Brazilian Biodiversity coupled with the latest advancements in omics, analytical, and data analytics technologies, promoting the re-emergence of natural products as a platform to discover and develop new ingredients (pharmaceuticals and nutraceuticals).
Nintx owns cutting-edge proprietary technologies (GAIApath® and xGIbiomics®) to understand natural products, biological targets, and the gut microbiome.
Nintx has established partnerships with research institutes and private companies that bring both complementary technical expertise and financial resources (US$ 3 million) as well as investments from Pitanga, Mov Investimentos, Ecoa Capital and partners, Adeste, Tiaraju, Maraé Investimentos, and Peter Andersen (US$ 10 million). Nintx also obtained relevant grants from FINEP and PIPE/Fapesp (US$ 3 million).
Katia Sivieri
Head of Microbiome Research
Rita Pessotti
Senior Researcher
Felipe Lemos
Financial and Administrative Manager
R&D: The Challenge
Most diseases are multifactorial, caused by genetic and environmental factors, as well as interactions between them (directly or via the human microbiome). Multifactorial diseases are unmet medical needs that affect the lives of millions of people globally and represent a multi-billion dollar market. Several multifactorial diseases are linked to the human gut microbiome.
Leadership
Stephani Saverio (CEO)
Chief Executive Officer
Cristiano Guimarães (CSO)
Chief Scientific Officer
%20Revisada_edited.jpg)
Miller Freitas (CDO)
Chief Development Officer
Scientific Advisory Board: Fernando Reinach, Eduardo Zimmer, Katia Sivieri
Board of Directors: Stephani Saverio, Miller Freitas, Cristiano Guimarães, Peter Andersen, Gabriel Perez, Paulo Bellotti, Mariana Donatelli, Tomaz Moura
Genetic Factors
Genetic mutations Epigenetics
Gene expression
Environmental Factors
UV radiation Metals
Chemicals
Toxins
Dust
Water
Nutrition
Lifestyle
Stress
MULTIFACTORIAL DISEASES
INTERACTION
Cancer
-
Melanoma
-
Liver
-
Pancreatic
-
Colorectal
Metabolic diseases
-
Obesity
-
Type 2 diabetes
-
Non-alcoholic fatty liver disease
Respiratory diseases
-
Chronic obstructive pulmonary disease
-
Asthma
-
Ulcerative colitis
-
Crohn's disease
IBD
-
Psoriasis
-
Vitiligo
-
Atopic dermatitis
Skin diseases
Brain disorders
-
Autism spectrum disorder
-
Schizophrenia and
bipolar disorder -
Neurodegereration:
Parkinson's disease
Alzheimer's disease
A missing link
The human microbiome
Team (Nintxers)
R&D: The Solution
R&D: Nintx's Platform
R&D: Pipelines
NTX-01
Cardiometabolic – indication undisclosed
NTX-02
Infectious diseases – indication undisclosed
NTX-03
Cardiometabolic – liver/cardiac regeneration
NTX-04
NTX-05
Pharmaceuticals
Immunology – immuno-oncology
Gastroenterology – irritable bowel syndrome
NTX-06
Gastroenterology – inflammatory bowel disease
NTX-07
Neuroscience – Alzheimer’s disease
NTX-08
Multiple TAs – indication undisclosed
PBTX-01
Newborn gastrointestinal health
PBTX-02
Digestive support for non-celiac gluten sensitivity
PBTX-03
Broad-spectrum digestive support for adults
PBTX-04
Nutraceuticals
PBTX-05
Irritable bowel syndrome
Gut barrier restoration
PBTX-06
Digestive support for non-celiac gluten sensitivity + Gut barrier restoration
PBTX-07
Microbiome gut-brain axis modulation
PBTX-08
Histamine intolerance
R&D: Nintx's Technologies
Nintx’s proprietary data analytics knowledge graph infrastructure to map and select medicinal plants from nature’s biodiversity with the ability to modulate targets and the gut microbiome concomitantly.
Nintx’s proprietary platform is able to emulate the human gastrointestinal digestive system and gut microbiome (pH, volume, agitation, flow rate, temperature, enzymes, microorganisms, anaerobiosis, O2 level control, metabolites). It is a state-of-the-art technology, extremely rare in both academia and the private sector, to study the human gut microbiome modulation after both short-term and long-term interventions.